ATE485258T1 - Glycyrrhetinsäurederivate und ihre verwendung zur herstellung eines medikaments zur hemmung der 11- beta-hydroxysteroid dehydrogenase - Google Patents
Glycyrrhetinsäurederivate und ihre verwendung zur herstellung eines medikaments zur hemmung der 11- beta-hydroxysteroid dehydrogenaseInfo
- Publication number
- ATE485258T1 ATE485258T1 AT02704938T AT02704938T ATE485258T1 AT E485258 T1 ATE485258 T1 AT E485258T1 AT 02704938 T AT02704938 T AT 02704938T AT 02704938 T AT02704938 T AT 02704938T AT E485258 T1 ATE485258 T1 AT E485258T1
- Authority
- AT
- Austria
- Prior art keywords
- acid derivatives
- medication
- beta
- inhibiting
- producing
- Prior art date
Links
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical class C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 title 1
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960003387 progesterone Drugs 0.000 abstract 1
- 239000000186 progesterone Substances 0.000 abstract 1
- 150000003145 progesterone derivatives Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Lubricants (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0105772.8A GB0105772D0 (en) | 2001-03-08 | 2001-03-08 | Use |
| PCT/GB2002/001060 WO2002072084A2 (en) | 2001-03-08 | 2002-03-07 | Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE485258T1 true ATE485258T1 (de) | 2010-11-15 |
Family
ID=9910270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02704938T ATE485258T1 (de) | 2001-03-08 | 2002-03-07 | Glycyrrhetinsäurederivate und ihre verwendung zur herstellung eines medikaments zur hemmung der 11- beta-hydroxysteroid dehydrogenase |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040147494A1 (de) |
| EP (1) | EP1381357B1 (de) |
| AT (1) | ATE485258T1 (de) |
| AU (1) | AU2002238737A1 (de) |
| DE (1) | DE60238042D1 (de) |
| GB (1) | GB0105772D0 (de) |
| WO (1) | WO2002072084A2 (de) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020351D0 (en) | 2000-08-17 | 2000-10-04 | Catalyst Biomedica Ltd | Treatment of hyperproliferative diseases |
| GB0107383D0 (en) * | 2001-03-23 | 2001-05-16 | Univ Edinburgh | Lipid profile modulation |
| JP4601936B2 (ja) * | 2002-10-29 | 2010-12-22 | 株式会社ミノファーゲン製薬 | Ｍｃｐ−１産生抑制のための薬学的組成物 |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| DE10307388A1 (de) * | 2003-02-21 | 2004-09-02 | Cognis Deutschland Gmbh & Co. Kg | Glyzyrrhetinsäureester |
| WO2004075831A2 (en) * | 2003-02-21 | 2004-09-10 | Merck & Co., Inc. | Pharmacodynamic assay for inhibitors of 11-beta-hydroxysteroid dehydrogenase activity in animal tissues |
| US20040180332A1 (en) * | 2003-03-12 | 2004-09-16 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating aids and HIV-related disorders using 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777 |
| US7501405B2 (en) | 2003-04-11 | 2009-03-10 | High Point Pharmaceuticals, Llc | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
| EP1615667A2 (de) * | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Kombinationspräparate welche einen 11-beta-hydroxysteroid-dehydrogenas typ-3 hemmer und einen glucocorticoid rezeptor agonist enthalten |
| DE10340747A1 (de) * | 2003-08-29 | 2005-04-07 | Ludwig Prof. Dr. Wildt | Stimulierung des Brustwachstums durch Erhöhung der intrazellulären Cortisolkonzentration |
| ATE416761T1 (de) * | 2003-09-22 | 2008-12-15 | Onepharm Res & Dev Gmbh | Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund |
| GB0325745D0 (en) * | 2003-11-05 | 2003-12-10 | Astrazeneca Ab | Chemical compounds |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| DE102004040690A1 (de) * | 2004-08-20 | 2006-03-02 | Universitätsklinikum Schleswig-Holstein | Selektiver Inhibitor der 11beta-Hydroxysteroid Dehydrogenase |
| GB0418877D0 (en) * | 2004-08-24 | 2004-09-29 | Univ Edinburgh | Heart |
| WO2006097337A2 (en) * | 2005-03-18 | 2006-09-21 | Onepharm Gmbh | 11β-HYDROXYSTEROID DEHYDROGENASES |
| WO2006105127A2 (en) * | 2005-03-31 | 2006-10-05 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
| CN100488979C (zh) * | 2005-10-14 | 2009-05-20 | 天津药物研究院 | 甘草次酸-30-酰胺类衍生物及其用途 |
| GB0523550D0 (en) * | 2005-11-18 | 2005-12-28 | Hunter Fleming Ltd | Therapeutic uses of steroidal compounds |
| US20100087385A1 (en) * | 2006-02-17 | 2010-04-08 | Hong Ding | Application of glycyrrhizic acid and its breakdown product glycyrrhetinic acid for the manufacture of a medicament for the treatment of inflammatory bowel disease |
| WO2008071169A2 (de) * | 2006-12-11 | 2008-06-19 | Universitätsklinikum Schleswig-Holstein | Verfahren zur herstellung spezifischer inhibitoren der 11beta-hydroxysteroid-dehydrogenase, insbesondere des typs 1, mit nor-oleanan- oder nor-ursan-grundgerüsten |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| MX2009013293A (es) | 2007-06-04 | 2010-02-15 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos. |
| EP2810951B1 (de) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase |
| CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP2348857B1 (de) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Neue cyclische benzimidazolderivate als antidiabetika |
| JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
| MX2011005037A (es) | 2008-11-21 | 2011-06-16 | High Point Pharmaceuticals Llc | Compuestos de adamantilo benzamida. |
| EP2243494A1 (de) * | 2009-04-22 | 2010-10-27 | OntoChem GmbH | Arzneimittelzusammensetzung, enthaltend einen Steroid-dehydrogenase-reduktase-Hemmer und einen Mineralocorticoidantagonisten. |
| CN101899081B (zh) * | 2009-05-31 | 2012-09-05 | 江苏正大天晴药业股份有限公司 | 甘草次酸酯类衍生物合成方法以及脱氧甘草次酸酯化合物 |
| ES2350077B1 (es) | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
| AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US8513430B2 (en) | 2010-07-27 | 2013-08-20 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| TW201221524A (en) * | 2010-11-23 | 2012-06-01 | Univ Fu Jen Catholic | A compound used to improve diseases caused by aquaporin deficiency |
| MX348131B (es) | 2011-02-25 | 2017-05-26 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos. |
| CA3100941C (en) | 2011-03-01 | 2024-03-05 | Synergy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
| WO2013101719A2 (en) * | 2011-12-27 | 2013-07-04 | Northeast Ohio Medical University | Amooranin compounds and analogs thereof and related methods of use |
| WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US20160009755A1 (en) * | 2013-03-01 | 2016-01-14 | Revlon Consumer Products Corporation | Cyrrhetinic alkyl esters and protected derivatives thereof |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| EA201592263A1 (ru) | 2013-06-05 | 2016-05-31 | Синерджи Фармасьютикалз, Инк. | Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3057977A4 (de) * | 2013-10-15 | 2017-07-26 | President and Fellows of Harvard College | Verfahren und zusammensetzungen zum entfernen von leukämiezellen |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298B1 (de) | 2016-12-20 | 2026-03-11 | Merck Sharp & Dohme LLC | Antidiabetische spirochromanverbindungen |
| CN111018938B (zh) * | 2019-12-10 | 2021-05-25 | 中国人民解放军第二军医大学 | 一种五环三萜类甘草次酸衍生物及制备方法与应用 |
| CN115677813A (zh) * | 2021-03-25 | 2023-02-03 | 河北中医学院 | 化合物在tmem16a激动剂中的应用 |
| CN113912665B (zh) * | 2021-12-01 | 2023-03-28 | 河北维达康生物科技有限公司 | 一种合成3-甲氧基-18β-甘草次酸的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3859328A (en) * | 1971-11-03 | 1975-01-07 | Pfizer | 18 beta-glycyrrhetinic acid amides |
| US3766206A (en) * | 1971-11-03 | 1973-10-16 | Pfizer | 18beta-glycyrrheting acid amides useful as antiulcer agents |
| US3934027A (en) * | 1973-05-03 | 1976-01-20 | Pfizer Inc. | 18β-Glycyrrhetinic acid amides useful as antiulcer agents |
| GB1570394A (en) * | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| IT1075675B (it) * | 1977-03-16 | 1985-04-22 | Isf Spa | Derivati dell'acido oleanoico |
| JPS588044A (ja) * | 1981-07-06 | 1983-01-18 | Maruzen Seiyaku Kk | １１−デオキソグリチルレチン酸水素マレ−ト及びそれを有効成分とする医薬 |
| JPS63135351A (ja) * | 1986-11-28 | 1988-06-07 | Sanwa Kagaku Kenkyusho Co Ltd | グリチルレチン酸誘導体、その製法及び該化合物を有効成分とする抗潰瘍剤 |
| GB9517622D0 (en) * | 1995-08-29 | 1995-11-01 | Univ Edinburgh | Regulation of intracellular glucocorticoid concentrations |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
-
2001
- 2001-03-08 GB GBGB0105772.8A patent/GB0105772D0/en not_active Ceased
-
2002
- 2002-03-07 DE DE60238042T patent/DE60238042D1/de not_active Expired - Lifetime
- 2002-03-07 EP EP02704938A patent/EP1381357B1/de not_active Expired - Lifetime
- 2002-03-07 US US10/469,954 patent/US20040147494A1/en not_active Abandoned
- 2002-03-07 AT AT02704938T patent/ATE485258T1/de not_active IP Right Cessation
- 2002-03-07 WO PCT/GB2002/001060 patent/WO2002072084A2/en not_active Ceased
- 2002-03-07 AU AU2002238737A patent/AU2002238737A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002072084A3 (en) | 2002-11-21 |
| EP1381357B1 (de) | 2010-10-20 |
| DE60238042D1 (de) | 2010-12-02 |
| EP1381357A2 (de) | 2004-01-21 |
| WO2002072084A2 (en) | 2002-09-19 |
| WO2002072084A8 (en) | 2003-01-09 |
| AU2002238737A1 (en) | 2002-09-24 |
| GB0105772D0 (en) | 2001-04-25 |
| US20040147494A1 (en) | 2004-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60238042D1 (de) | Glycyrrhetinsäurederivate und ihre verwendung zur herstellung eines medikaments zur hemmung der 11-beta-hydroxysteroid dehydrogenase | |
| SE0001899D0 (sv) | New compounds | |
| NO20042596L (no) | Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1 | |
| UA85708C2 (ru) | Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей | |
| SE0202462D0 (sv) | Novel use | |
| DE60305514D1 (de) | Neue verwendung von benzothiazolderivaten | |
| WO2005037825A3 (en) | Protein kinase inhibitors | |
| WO2006034833A1 (en) | Cyclic diarly ureas suitable as tyrosine kinase inhibitors | |
| ATE373474T1 (de) | Substituierte 2-aminotetraline zur behandlung von depressionen | |
| MY134582A (en) | New fluorenecarboxylic acid esters, process for the manufacture thereof and use thereof as medicaments | |
| DE60045508D1 (de) | Dalda-analoge und ihre verwendung | |
| DE60202958D1 (de) | Stabiles polymorph von flibanserin, industrielles verfahren zu dessen herstellung und dessen verwendung zur herstellung von medikamenten | |
| MY133527A (en) | Isoquinoline derivatives | |
| DE602004015406D1 (de) | Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen | |
| SE9903894D0 (sv) | Novel compounds | |
| TW200616636A (en) | Novel compounds | |
| MXPA04007643A (es) | Inhibidores de la adhesion celular mediada por integrina alb2. | |
| DE602004025935D1 (de) | Histondeacetylaseinhibitor und verfahren zu dessen herstellung | |
| DE502005003310D1 (de) | Cycloalkyl substituierte 7-amino-4-chinolon-3-carbonsäure-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| TW200640465A (en) | New pharmaceutically active compounds for the treatment of respiratory diseases | |
| MXPA06004307A (es) | Derivados de benzazepina como inhibidores de mao-b. | |
| EP1949893A3 (de) | Chinazolinderivate als Phosphodiesterasehemmer zur Verwendung für die Behandlung peripherer Arterienerkrankungen | |
| ATE408403T1 (de) | Deramciclan-enthaltende pharmazeutische zusammensetzung für die behandlung der verringerung kognitiver funktionen und/oder schäden davon | |
| WO2004065360A3 (en) | Piperazine derivatives and their use as synthesis intermediates | |
| DE602005017629D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |